secwatch / observer
8-K filed September 12, 2024, 7:59 PM ET ticker AUPH CIK 0001600620
leadership confidence high sentiment neutral materiality 0.60

Aurinia restructures board: 3 directors resign, Kevin Tang appointed, CEO Greenleaf stays

Aurinia Pharmaceuticals Inc.

item 5.02item 7.01item 5.03item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kevin Tang

Director
AUPH · Aurinia Pharmaceuticals Inc.
Effective
2024-09-12
Filed
September 12, 2024, 7:59 PM ET
Effective September 12, 2024, the Board appointed Kevin Tang, President of Tang Capital Management, LLC, a life sciences-focused investment company that he founded in 2002, as member of the Board.
Departed

Brinda Balakrishnan

Director
AUPH · Aurinia Pharmaceuticals Inc.
Effective
2024-09-09
Filed
September 12, 2024, 7:59 PM ET
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
Departed

R. Hector MacKay-Dunn

Director
AUPH · Aurinia Pharmaceuticals Inc.
Effective
2024-09-09
Filed
September 12, 2024, 7:59 PM ET
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
Departed

Daniel G. Billen

Director
AUPH · Aurinia Pharmaceuticals Inc.
Effective
2024-09-09
Filed
September 12, 2024, 7:59 PM ET
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kevin Tang was appointed as Director at Aurinia Pharmaceuticals Inc..

Action
appointed
Role
Director
Exact text from the filing
Effective September 12, 2024, the Board appointed Kevin Tang, President of Tang Capital Management, LLC, a life sciences-focused investment company that he founded in 2002, as member of the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Brinda Balakrishnan resigned as Director at Aurinia Pharmaceuticals Inc..

Action
resigned
Role
Director
Exact text from the filing
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

R. Hector MacKay-Dunn resigned as Director at Aurinia Pharmaceuticals Inc..

Action
resigned
Role
Director
Exact text from the filing
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Daniel G. Billen resigned as Director at Aurinia Pharmaceuticals Inc..

Action
resigned
Role
Director
Exact text from the filing
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
View on SEC.gov

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR
accession 0001600620-24-000099
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.